Exicure, Inc
Exicure, Inc. is a U.S.-based early-stage biotechnology company that historically developed nucleic acid therapies, but has since halted research and development and is now focused on strategic alternatives. The company has monetized parts of its legacy intellectual property through licensing and asset sales, while also pursuing financing and other transactions to preserve optionality.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLicensing of patents and related rights tied to historical drug candidates and technologies.
Sale of legacy biotechnology assets, samples, and other non-core IP holdings.
Potential future royalties from licensed technologies, subject to third-party commercialization.
Financing, acquisitions, partnerships, and other strategic alternatives to preserve value.
Customers
Exicure’s direct counterparties are primarily biopharmaceutical companies that license patents or acquire assets tied to its historical programs. In the current phase, the company is less of a product seller and more of an IP holder seeking monetization through licensing, royalties, and transaction structures. Any future economic value depends on third parties advancing the licensed technologies or on successful strategic transactions.
Companies that license Exicure patents or technology to develop and commercialize drug candidates.
Buyers of legacy intellectual property, samples, and other non-core biotech assets.
Potential acquirers, partners, or investors involved in restructuring or value-maximizing deals.
Commercial partners whose product sales could trigger modest royalty streams.
Strategy
Exicure’s strategy is no longer centered on internal drug development; it is focused on preserving value through strategic alternatives, licensing, asset sales, and external financing. Management is trying to monetize legacy intellectual property while maintaining enough liquidity to continue operating and evaluate transactions. The company’s near-term direction is driven by survival, optionality, and the possibility of a restructuring or sale.
Liquidity is insufficient to fund obligations and strategic exploration.
The company needs a transaction path to preserve or realize remaining value.
Licensing and royalties are the main remaining sources of potential value.
Geography
Exicure is headquartered in the United States and its reported business activity is centered there. The company’s current operations are primarily domestic, with counterparties and financing activity also appearing to be U.S.-based. Because the company is in a monetization and restructuring phase, geography matters mainly through access to U.S. capital markets, legal processes, and domestic biotech partners.
Risks
Exicure faces severe going-concern risk because current liquidity is not sufficient to fund operations, and management has disclosed the possibility of bankruptcy or cessation of operations. The business also depends on uncertain licensing, royalty, and transaction proceeds that are outside its control, while any new capital raise could be highly dilutive. As a small biotech shell with limited revenue, it is also exposed to legal, regulatory, and public-company overhead that can overwhelm remaining resources.
Cash is not sufficient to fund obligations and operations without new financing.
Exposure: Operating survival
Future capital may come from equity or convertible debt with dilution or covenants.
Exposure: Shareholder value
Royalties and license fees depend on third-party development and commercialization.
Exposure: Future revenue
Administrative, regulatory, accounting, and IT costs remain despite limited operations.
Exposure: Cash burn
Any remaining value depends on assets in a highly uncertain drug-development sector.
Exposure: Legacy technology value
Accounting
Judgemental itemsReported gains or losses from remeasurement can materially swing earnings.
Impact: Other income/expense volatility
Recoverability depends on uncertain future cash flows from legacy assets.
Impact: Potential write-downs
Acquired biotech intangibles require subjective assumptions on success and cash flows.
Impact: Goodwill/intangible valuation and amortization
Upfront fees, milestones, and royalties may be recognized at different times.
Impact: Lumpy revenue and margin timing
Similar listed companies
Publicly listed companies with a comparable business focus.
Xencor Inc
XNCR · Pharmaceutical Preparations
eXoZymes Inc
EXOZ · Biological Products, (No Diagnostic Substances)
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Scienture Holdings, Inc.
SCNX · Pharmaceutical Preparations
Last updated: 28/04/2026